Summary. Preclinical experiment on multi-drug combination has an increasingly important role in (especially cancer) drug development because of the need to reduce development time and costs. Despite of recent progresses in statistical methods for assessing drug interaction, there is a lack of general method for experimental design for such studies. We propose a general method for determining the doses comprising the combinations and the sample sizes to detect departures from additivity especially in the case of more than two drugs in a semi-parametric statistical model. We utilize the uniform scattered points in the experimental domain to determine the doses comprising the combinations and calculate the sample size so that the power to detect departure from additivity is maximized. To our surprise, such an extension to multi-drug is far more difficult than what it appears when there are three or more drugs involved. Using the general methodology, we derive the combinations and sample size specifically for a common class of drugs to derive the experimental design. In addition, we illustrate the method with the SAHA and Ara-C and Etoposide combination studies.
Introduction
The study of the joint action of drugs has a long history in pharmacology and biostatistics (see, e.g., Finney, 1971 ; and reviews by Berenbaum, 1989; Greco et al., 1995) .
Synergism/super-additivity (antagonism/sub-additivity) commonly refers to a dose-effect greater (lesser) than what would be predictable based on knowledge of single drugs if they are additive. Although several definitions of additivity exist, the statistical (as opposed to mechanistic) Loewe's additivity has been shown to be a generally applicable definition and has thus been the primary accepted definition in the evaluation of drug synergy/antagonism (Berenbaum, 1989; Greco at al., 1995) . The Loewe additivity is implied when the doses in a combination contribute to the dose-effect according to individual drug potencies (see more details in Section 2). Throughout this paper, this definition will be used, and compounds, agents and drugs will all be referred to as drugs. Because of the importance of drug combinations in cancer, antiviral and antimicrobial therapies, research on synergy has recently attracted increased attention from statisticians (see, e.g., Tan et al., 2003; Kong and Lee, 2006; Lee and Kong, 2008; Fang et al., 2008) . A statistical approach to the design and analysis of drug combinations becomes a natural choice because of large variations in dose effect observed in the administration of precisely the same dose to virtually genetically identical animals (or even different aliquots). What makes the biological experiment unique is that the inter animal (run-to-run) variation is typically much greater than that in a typical industrial (e.g., mechanical or chemical engineering)
experiment. In addition, these experiments are costly and sample sizes (e.g., the number of animals) should not be larger than necessary. Statistical experimental design attempts to control and account for the variation in both the design and the analysis stages. The key statistical design issues are to find the doses in the combinations and determine sample sizes (how many combinations and replications at each combination) to detect departures from additivity. Although a PubMed search of "synergy" generated over 40,000 articles up to the year of 2007 on the subject, few of them address experimental design issues such as dose-finding and sample size determination in such experiments.
In designing a combination study, the model of the joint action is typically not well specified and the constituent doses in the combinations are to be found instead of being given. One common feature of more classic designs is allocating the doses of one drug only while keeping the doses of another drug fixed under the assumption of constant relative potency (see, e.g., Finney , 1971; Abdelbasit and Plackett, 1982; Tallarida et al., 1997; Laska et al., 1994; Gennings et al., and 2004; Straetemans et al., 2005) . Hence, the design is suboptimal. In addition, by ignoring the three dimensional nature of the dose response surface, these methods examine multiple combinations and are prone to giving false synergistic combinations (Dawson et al., 2000) or missing an apparent interaction at a particular combination due to inadequate statistical power. Recognizing these unique features, recently Tan et al., 2003; and Fang et al., 2008) developed a design based on uniform measures (to select the combinations and calculate the sample size (the number of replicates at the selected combinations) to detect departures from additivity under the more realistic setting of nonconstant relative potency. This design is similar in spirit to a space-filling type design but the dose levels have to be determined instead of being given (page 181-191, Cox and Reed, 2000) . Unfortunately, the method is limited to two drug combinations. Contrary to what we expect, the extension of the method to multidrug combination turns out to be a challenge as shown later in this article because of the increased complexity in the additive model and in obtaining uniform scattered points in high dimensional dose regions. This may partially explain why design for three drug combination is not available despite of the need for such studies.
In this article, we propose an experimental design for detecting departures from additivity of multiple drugs in preclinical studies in a general statistical setting. The design is derived by the uniform measures that maximizes the power to detect any overall possible departures of a given magnitude from additivity while minimizing the lack of fit of the model for joint action. Thus we refer the design as maximum power design for brevity.
This general framework does not require constant relative potency and is flexible enough to include the design to test joint action of multiple drugs from multiple different classes of drugs in both in vitro and in vivo experiments. Section 2 formulates the general statistical model for the joint action of drugs and proposes an F -statistic to test if additive action presents. The maximum power design to determine doses and sample sizes for testing joint action based on the general statistical model is derived in §3. In Section 4, we focus on the experimental design the common log-linear dose-response curve and show why it is so difficult to derive the design with combinations of three or more drugs. Section 5 illustrates the proposed design method with a study on three anticancer drugs, where the proposed method identified a synergistic combination that would have been missed and that is currently being tested in a clinical trial. We conclude with a discussion in §6 and the more theoretic results on the design are included in the Appendix.
Model formulation and statistical inference framework

Consider a combination of k drugs
Dose-response relationships for individual drugs are estimated by regression models and are given by
where y is the dose-effect scaled to be a viability (proportion of cells surviving) or a tumor volume (with some transformation) and f i (X i ) is assumed to be an increasing function of X i in the dose range of interest. Then, the potency of drug A i relative to drug A 1 is the ratio of isoeffective doses of A 1 and
, denote the combination dose-effect (response) by f com (x 1 , . . . , x k ). According to Loewe's definition, the isoboles (isoeffect equation) of the k drugs is defined as (see (1a) in Berenbaum, 1989 ),
where X i represents the dose of the ith drug alone that yields the same response as the From (2.3) and (2.4), we have that
and the term [f 1 (X 1 ) − f 1 (τ X 1 )] = 0 if the joint action of A 1 , . . . , A k is additive. Then, the regression line for the combination with additive action of k drugs is
2) is not a constant, the additive model (2.5) has no closed forms.
Since we generally know little about the joint effect of the combinations before experiments, we consider a general semiparametric model for the joint effect of the k drugs in the experimental domain S 0 , 6) where the function f is unspecified, ε is the error term due to variation in experiments and is assumed to be normally distributed with mean 0 and variance σ 2 . Then, testing the additive action of the k compounds is equivalent to testing the hypothesis H 0 : f = 0.
To derive the experimental design, we first assume that model (2.5) has (or is approximated by) a generalized additive structure, namely, additive after transformation. For example, we have an approximate additive structure with polynomial approximation since the additive model with a non-constant potency has no closed form. As further detailed in Section 4, such approximation can be achieved once the individual dose-response or the class of drugs is given. Suppose that there is a one-to-one invertible transformation:
such that the additive model (2.5) can be expressed as 8) where the functions g 1 , . . . , g k are linearly independent, and
where η is a given magnitude of synergism or antagonism worth detecting and V(S) is the volume (or area) of the domain of experiment S (see below). Then model (2.6) becomes satisfies the following orthogonality condition: 10) where
Consequently, the experimental design for the k drug combinations is transformed into
in domain S with model (2.9). When there are m experimental points
. . , m, in the experimental domain S, we can obtain the dose-levels x Hence, testing the additive action of k drugs is equivalent to testing the hypothesis
The test is powered at a given magnitude η(> 0) of departure from additivity worth
then the combinations of k drugs are still considered additive. The amount η is the smallest synergy (antagonism) of significance, which is usually based on medical and pharmacological knowledge and especially investigators' experience in a particular class of drugs.
In fact, the test statistic can be derived based on the common lack of fit test involving least square error estimates under the full model (2.9) and the additive model (2.5).
Assume that the m points in the experimental domain are z
, and there are n i experiments at the dose-level z
T ∈ S with corresponding responses
Let y be the n × 1 vector with elements y ij ordered lexicographically and 1 1 k be the k × 1 vector of one. Let Z be the m × k matrix with ith row (g 1 (z
hypothesis H 0 is true (i.e, the joint action of the k drugs is additive), the statistic for the test of lack of fit
has a central F -distribution with degrees of freedom m − k and n − m (see Wiens, 1991 ). When the alternative hypothesis H 1 holds, the statistic (2.12) has a noncentral F -distribution with degrees of freedom m − k and n − m and the noncentrality parameter
where
and ξ is the design measure, which is a probability distribution function with mass
Experimental design based on uniform measures
Recall our goal is to select the m combinations of drugs, z
, . . . , z (m) in domain S such that the power of the F -test in (2.12) is maximized at a given type I error level and the variability in modeling joint action is minimized. The power of the test is an increasing function of the noncentrality parameter δ given by (2.13). The quantity B(g, ξ) is a function of both g and the design measure ξ. Let F − η be the class of functions whose element g satisfying conditions (2.10) and (2.11), and F + η be the class of functions defined again by (2.10) and (2.11) as in F − η but with the inequality in (2.11) reversed. Wiens (1991) proved that for any design ξ there are an g + ∈ F
where λ is the uniform distribution on S. Since the least squares estimate of σ
we have Therefore, if we choose the design measure ξ to be uniform on S, then the noncentrality parameter δ is maximized and (2.13) becomes
It is worthwhile to point out that the experimental points obtained are the uniformly scattered points by the number theory method (NTM), but not random numbers generated from a uniform distribution. Although they are more difficult to obtain, the uniformly scattered points by NTM are more uniform (with smaller discrepancy) and more efficient than those by random numbers from a uniform distribution (see Appendix for more details). The design where experimental points are uniformly scattered based on a uniform design measure in the experimental domain is called the uniform design proposed by Fang and Wang (see, Fang and Wang, 1994; Fang et al., 2000) .
Uniform design and uniform scattered points
To obtain uniform scattered points in the experimental domain, i.e., allocating the combinations for the experiment, potentially any NTM generation may apply. We utilize the U-type design of an m × k matrix U m,k = (u ij ) with each column being a permutation of {1, 2, . . . , m} (Fang and Wang, 1994) . Then the m points on the k-dimensional unit cube
Let U m,k denote the set of all U m,k and V m,k be the set of all V m,k . Then the uniform design is to choose the m points so that the discrepancy of V m,k is the smallest over all of possible V m,k in V m,k . Many U-type design matrices with smallest discrepancy can be found in Fang (1994) .
Based on the uniform scattered points on C k , it is easy to obtain the uniform design on the domain S and the combinations of the drugs for experiment. Given the single-drug dose response models, the domain S we are interested is, e.g., from ED20 to ED80, or some ranges based on the amount of systemic exposure or growth inhibition of cells in a particular experiment. Suppose that the domain
obtained by the U-type method. The m uniform design points on S are given by
Then, the m combinations of k drugs A 1 , . . . , A k for the combination experiment can be obtained by the inverse transform of (2.7).
Sample size determination
Suppose that the experimental points are uniformly scattered on the domain S and the number of runs (experiment units) at each point is the same. The sample sizes (number of experimental units) to detect a given meaningful synergism or antagonism can be calculated at a given significance level (α) and a given power level (1 − β) based on the F -statistic in (2.12). At a given alternative η, the smallest meaningful difference to be detected, the statistic F has a noncentral F -distribution with degrees of freedom m − k and n − m and the noncentral parameter δ in (3.1). Then the sample size calculation can be raedily implemented with SAS or Splus. Table 1 provides several illustrative designs for which numbers of experimental units and replications (1-6) with the several different effects to detect at given α = 0.05 and 1 − β = 80% for k = 2 and 3. From this table, the more replications are at each combination, the less is the total number of experiments. However, there should be at least k + 1 experimental units for the combination experiments of k drugs and at least one replication at each unit. It is worth noting that with the same replication at each mixture, the total experimental units for detecting departures from additivity in three drug combinations are slightly less than those in two drugs combinations. In practice, we should choose more experimental combinations with less replications for the combination study of more drugs. The balance of the number of combinations and the number of replications is based on knowledge about the specific drugs. For example, if the variation among animals is known to be substantial, the number of replications may need to be slightly higher.
[insert Table 1 and tumor promoters, and in general toxicology (see Berenbaum, 1989) . We show how to use the general framework to derive experimental designs for log-linear individual doseresponse curves. Assume that the single dose-response curves of drugs A, B and C are
respectively, where y is the dose-effect scaled into viability (proportion of cells surviving) or a tumor volume (with some transformation). Without loss of generality, we assume
and the potency ρ(X C ) of C relative to A is
When β C = β A , the potencies ρ(X B ) and ρ(X C ) above are constant and equal to ρ 0 and ρ 1 , respectively. In this case, the additive model at combination dose (
According to Section 2, the m experimental points {(z
3 ), i = 1, . . . , m} which maximize the statistical power in detecting synergy should be uniformly scattered in the 
(4.8)
The m combinations {(x
C ), i = 1, . . . , m} can be obtained by the inverse transformation of (4.7). When β C < β A , the potency ρ(X C ) depends on the dose-level X C . Then, based on (2.5), the additive model at combination dose (
where ψ is a function of (x A , x B , x C ) and can be obtained by solving the following equation
As alluded to earlier, the difficult is to find an approximation of the additive model (4.9).
Since the right-hand side of (4.10) approximates to
then, an approximate solution of (4.9) is given by
The additive model (4.9) becomes
(4.13) Similarly, the m experimental points {(z
3 ), i = 1, . . . , m} which maximize the statistical power in detecting synergy should be uniformly scattered in the experimental
C ), i = 1, . . . , m} can be obtained by the inverse transformation of (4.13). If we consider the combination experiments of only two drugs A and B, the additive
(4.14)
where φ(x A , x B ) can be obtained by solving the following equation
we have
(4.17)
2 ), i = 1, . . . , m} which maximize the statistical power in detecting synergy should be uniformly scattered in the
and the m combinations
{(x (i)
A , x (i) B ), i = 1, . . . , m} can be obtained by inverse transformation of (4.17),
(4.18)
When β A = β B , the potency of drug B relative to drug A is ρ 0 and the additive model 19) where z = x A + x B and π A = x A /z. This reduces to the special case discussed in Tan et al. (2003) where the uniform measures design is obtained such that the total doses and the mixing proportions are uniformly scattered on the two-dimensional experimental
Example: Vorinostat Combined with Ara-C and Etoposide against HL-60
To illustrate the methods of experimental design for combination studies, we consider the experiments of Vorinostat (SAHA) combined with Ara-C and Etoposide against HL-60.
SAHA is a potent histone deacetylase inhibitor that induces cell growth arrest, differentiation, and apoptosis in transformed cells in culture and inhibits tumor growth in animal models. Ara-C is one of the most active agents available for treating acute leukemias.
Etoposide has been shown to be an effective anti-leukemia agent, particularly when given in combination with other chemotherapeutic agents. Etoposide exerts its effects by interfering with topoisomerase II activity, binding to and stabilizing the covalent linkage between topoisomerase II and DNA, and inhibiting the re-ligation of the resultant DNA double strand breaks. The goal of this experiment is to determine the effects of preadministration of SAHA on the pharmacokinetics of Ara-C and Etoposide against the leukemia cell line HL-60 (Shiozawa et al., 2006) . In the experiments for single agents, we have 56 observations with doses ranging from 0.1µM to 6µM for SAHA, 56 observations with doses ranging from 0.003µM to 0.6µM of Ara-C, and 64 observations with doses ranging from 0.01µM to 10µM of Etoposide. Then, the single dose-response curves for Ara-C, where
and
and this approximation is very well since max{|y(
To obtain uniform design for testing the joint action of Ara-C, Etoposide and SAHA , the dose range is chosen such that the endpoint, 100×viability, is from 20 to 80 for Ara-C.
Then, the total dose ranges from 0.0028µm to 0.3038µm in Ara , respectively, because of the total dose range according to Ara-C.
[insert Table 2 here]
Discussion
Utilizing information on the single dose-response curves, we have proposed a maximum power statistical design for testing drug synergism based on a general model for joint action of drugs where no-specific parametric form of the synergistic/antagonistic effect is assumed. An F -test is proposed for detecting synergism/antagonism of drugs in the experimental domain. Selecting doses that comprise the combinations uniformly scattered in the experimental domain maximizes the minimum power of the F -test for detecting departure from additivity. The power optimality is derived from the properties of uniform measures and by minimizing the variability in modeling the dose-effect while allocating the combinations reasonably to obtain best possible estimate of the dose response surface of the joint action. In fact, the uniform design for generating experimental combinations (the doses of each drug) using the quasi-Monte Carlo methods is an optimal fractional factorial design under a general majorization framework with exponential kernels (Zhang, 2005; Zhang et al., 2005) . Hickernell et al. (2005) showed using quasi-Monte Carlo methods instead of the Monte Carlo method usually improves accuracy of computing the integral of a function.
In drug combination studies, the fixed ratio or ray design chooses total doses based on an assumed dose-effect while fixing the ratio of doses of the two compounds. When the individual dose-response curves are linear in log dose, the proposed design extends the optimal design by Abdelbasit and Plackett (1982) and the uniform design (see Tan et al., 2003) . In general, the (especially, non-constant) relative potency of drugs is ignored in the fixed ratio design, which results in a non-uniformly scattered of combinations and the power to detect synergism is undermined. In addition, the fixed ratio design may miss an apparent interaction at a particular combination and is inadequate for the combination studies of three or more drugs.
More importantly, the number of experimental units and replicates (sample size) in the proposed design is feasible for both in vitro and/or in vivo experiments. Table 1 shows that the sample sizes for detecting departures for additivity of three drugs are not greater than those of two drugs. However, if the F-test shows that there is a synergism/antagonism of the three drugs, the regression analysis for fitting the response surface to find the best synergistic mixture of drugs may need more experimental combinations because there are more variables in the model. Hence, the precision of the estimated dose-response may need to be factored in determining the number of experimental mixtures and the number of replications at each combination should be considered.
However, despite of the general framework for the design of combination studies, it is critical that we can identify k linear independent functions g 1 (z 1 ), . . . , g k (z k ) that achieve good approximation in (2.8) and obtain uniformed scattered points in the experimental 
APPENDIX: Uniform Design
The uniform design is proposed by Fang and Wang (see, Fang and Wang, 1994; Fang et al., 2000) and has been widely used in industrial experiments. The uniform design points are a class of uniformly scattered points in the experimental domain. Suppose that there
where I{·} is the indicator function and all inequalities are componentwise. The discrepancy of P m can be defined by
where F (w) is the uniform distribution function on C k . This discrepancy is the SmirnoKolmogorov statistic for goodness-of-fit tests and has been universally accepted in quasiMonte Carlo methods. However, the discrepancy defined in (A2) is hard to computation.
In practice, an equivalent form, the central L 2 -discrepancy proposed by Hickernell (1998) ,
is used, where w Fang et al., 2000) .
Obviously, the smaller the discrepancy, the more uniformly scattered on C k the set of points P m is. Kiefer (1961) proved that if w
, . . . , w (m) are i.i.d according to the uniform
with probability one. However, Korobov (1959) and Hlawka (1962) pointed out independently that for a given prime number m, using the number-theoretic method (the good-lattice-point method), we can choose m points P m = {w
where the constant c(k) depends on k only. This fact indicates that P m generated by the Monte Carlo method is not uniformly scattered on C k with probability one.
The aim of the uniform design is to choose a set of m points P m in C With uniform design points in C k , we can generate uniformly scattered points in some convex polyhedrons using transformations. The following theorem is used to generate uniformly scattered points in a k-dimensional triangular prism (k ≥ 3).
Theorem. Let S(a 1 , . . . , a 6 ) denote a triangular prism in R 4(28) * : Numbers in the parentheses are the total experimental units (n = m(n 0 + 1)).
